ONCOCROSS

We identified a new indication of a drug candidate in Phase II.

We analyzed the transcriptome data of a new drug candidate that is in Phase II clinical trial, an asset of our collaborating pharmaceutical company. RAPTOR AI™ predicted that the drug candidate will show high efficacy in the liver disease treatment. We validated the efficacy through in vitro and in vivo validation and currently planning a clinical trials after filing a patent application. Our partner pharmaceutical company was able to add a clinical stage pipeline that has high unmet medical needs while saving 95% of the cost and almost 7 years that is required to reach phase I from early drug discovery.

The 1st L/O from an AI Biotech to a traditional pharmaceutical company.

We set sarcopenia as a target disease and ran RAPTOR AI™ to search for the drugs that will show efficacy in treating the disease. We identified two drugs that can show high efficacy when used simultaneously and validated them through in vitro and in vivo studies. We licensed out to Korea Pharma, which recorded the 1st L/O deal of an AI-developed drug from an AI Biotech to a traditional pharmaceutical company.

With ONCO-RAPTOR AI, we identified the most optimal cancer types for the anti-cancer drug preparing to begin clinical trials.

In collaboration with our partner pharmaceutical company, we identified an additional solid cancer indication optimized for anti-cancer drugs, originally developed as a blood cancer treatment, using ONCO-RAPTOR AI™. Currently we are preparing for phase 1 clinical trials jointly with partners, including additionally confirmed solid cancers.

ONCOfind AI™ will identify the primary cancer site.

CUP is a cancer type which metastasized cancer cells are found but the primary tumor site is unknown, and accounts for 3-5% of all cancers. Traditionally immunohistochemical staining method is used and can diagnose the location of the primary cancer with an accuracy of only 40-65%. Globally, about 5 companies are engaged in the CUP’s primary cancer location screening service business with an accuracy of around 79-90%, and in Korea, there are no companies engaged in this service. ONCOCROSS’ ONCOfind AI identifies the location of the primary cancer with up to 92% accuracy.